Abstract
Background: To investigate the effects of rosuvastatin on cardiac function and serum MPO, MMP-9 in patients with chronic heart failure. Methods: From Nov. 2010 to Dec. 2011, 60 patients with CHF hospitalized at the Department of Cardiology in the Second Hospital of Hebei Medical University was selected, including 26 cases of ischemic heart disease, 34 cases of non-ischemic heart disease.And after admission were randomly divided into control group and the statin group (rosuvastatin 10mg/day). (N1⁄430 cases). The levels of MPO and MMP9, 6-minute walking distance, echocardiography (the size of heart chambers, LVEF) and blood lipids profiles were measured at baseline and 7-10days, 6weeks after treatment. Results: Six weeks after treatment, LVEF (%), the 6-minute walking distance of statin group and the 6 minutes walking distance of control group was significantly increased than before treatment (44.17O12.91 vs 38.75O14.4, 437.12O46.17 vs 356.10O42.60, 433.82O58.66 vs 379.33O61.81, p < 0.05). In addition, 6 weeks after treatment, the indexes of LV, LA, RA in statin group were significantly reduced than before treatment (62.35O9.75 vs 63.92O9.98, 39.92O6.11 vs 42.19O5.66, 34.92O4.35 vs 38.13O5.85, p< 0.05))after 7-10 days and 6 weeks of treatment, serum MMP-9 level in statin group decreased significantly compared with that of control group((42.70O14.41 vs 73.55O32.30, 47.78O22.29 vs 69.22O21.66, p< 0.05). After 6 weeks
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
